Enzomenib
Enzomenib is an inhibitor of the menin protein encoded by the multiple endocrine neoplasia (MEN) gene. Enzomenib can block the binding of the menin protein to mixed lineage leukemia (MLL) fusion proteins and can be used in the study of hematological malignancies[1].
Product Specifications
CAS Number
2412555-70-3
Product Name Alternative
DSP-5336
UNSPSC
12352005
Target
Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/enzomenib.html
Purity
99.88
Solubility
DMSO : 83.33 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C([C@@H](N[C@]1([H])C2)[C@@](CC1)([H])C2=C)N3CCC4(CC3)CN(C5=NC=NC=C5OC(C=CC(F)=C6)=C6C(N(C(C)C)C(C)C)=O)C4
Molecular Formula
C33H43FN6O3
Molecular Weight
590.73
References & Citations
[1]Francis Burrows, et al. Treatment of hematological malignancies with inhibitors of menin. US2021/055644. 2022-04-28.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD30 / TNFRSF8 (Hodgkin & Reed-Sternberg Cell Marker) (rCD30/412), CF405S conjugate, 0.1mg/mL
